Oncotelic Therapeutics Inc. (OTC:OTLC), the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide (ASO) platform, fueled by promising clinical data and ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

The ability to make synthetic DNA and RNA by chemical or enzymatic means has revolutionized genetic research and drug discovery. Antisense technology employs short, chemically synthesized ...

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and ...

UCSC researchers will synthesize the top ASO designs proposed by Eterna players and test them in laboratory experiments. The UCSC team includes Victor Tse (above), a graduate student in MCD Biology.

A new pediatric brain cancer treatment uses a short RNA strand to shut down a deadly mutation. Introducing into a cell an exact match for a mutant protein’s mRNA, called an antisense oligonucleotide ...

SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, has engaged La Jolla Labs, a RNA drug discovery company, to support n-Lorem’s discovery efforts to provide personalized experimental ...

Researchers at UC Santa Cruz have developed a new puzzle challenge for the online game Eterna, enlisting players to help design a novel RNA drug to treat hemophilia A Researchers at UC Santa Cruz ...